ISHLT共识:持续流左心室辅助装置血液相容性不良事件的预防与管理
ISHLT发布共识声明,汇总当前文献证据,针对植入耐久性持续流左心室辅助装置(CF-LVAD)患者的血液相容性相关不良事件(HRAE),从口服抗凝药与抗血小板药、肠外抗凝药、高危及血栓/出血事件患者管理、非抗血栓药物装置管理等方面提出预防与管理策略,以协助临床医生优化诊疗。
要点
- CF-LVAD患者HRAE仍导致显著并发症与死亡,需重视预防与管理。
- 共识涵盖口服抗凝、抗血小板及肠外抗凝药物的优化管理策略。
- 需识别HRAE高危患者并管理已发生血栓或出血事件的患者。
核心结论
- 该ISHLT共识声明汇总当前文献,提出CF-LVAD患者HRAE预防与管理的综合策略,以协助临床医生提供最佳诊疗。
研究设计与样本
- 国际心肺移植学会(ISHLT)共识声明,基于当前文献的总结性评估。
主要发现
- CF-LVAD患者预期寿命持续延长,但HRAE仍是重要关切,发生时可导致显著并发症与死亡。
关键数值与推荐
- 共识涉及口服抗凝药与抗血小板药、肠外抗凝药的优化管理,高危患者及血栓/出血事件患者的管理,以及非抗血栓药物相关的装置管理。
临床怎么用
- 临床医生可参考该共识对CF-LVAD患者进行HRAE的预防与管理,包括抗血栓药物调整、高危患者识别和装置管理。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Life expectancy of patients with a durable, continuous-flow left ventricular assist device (CF-LVAD) continues to increase. Despite significant improvements in the delivery of care for patients with these devices, hemocompatability-related adverse events (HRAEs) are still a concern and contribute to significant morbility and mortality when they occur. As such, dissemination of current best evidence and practices is of critical importance. This ISHLT Consensus Statement is a summative assessment of the current literature on prevention and management of HRAEs through optimal management of oral anticoagulant and antiplatelet medications, parenteral anticoagulant medications, management of patients at high risk for HRAEs and those experiencing thrombotic or bleeding events, and device management outside of antithrombotic medications. This document is intended to assist clinicians caring for patients with a CF-LVAD provide the best care possible with respect to prevention and management of these events.
引用
- Hollis IB, Jennings DL, Krim S, et al. An ISHLT consensus statement on strategies to prevent and manage hemocompatibility related adverse events in patients with a durable, continuous-flow ventricular assist device. J Heart Lung Transplant. 2024. PMID: 38878021. doi:10.1016/j.healun.2024.04.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。